ArticleEuropean radiology2026
Efficacy and safety of thermal ablation for the treatment of recurrent and persistent secondary hyperparathyroidism: a multicenter retrospective study.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveTo evaluate the long-term efficacy and safety of Ultrasound (US)-guided percutaneous thermal ablation for recurrent or persistent secondary hyperparathyroidism (SHPT) and identify predictors of treatment failure. MATERIALS AND
methodsFrom January 2014 to July 2023, 102 patients with recurrent or persistent SHPT after parathyroidectomy or ablation received thermal ablation. The median follow-up period was 30 months. The primary endpoint was the proportion of participants who achieved target parathyroid hormone (PTH) levels (≤ 300 pg/mL) at the end of follow-up. The secondary endpoints were the mean changes in levels of PTH, calcium, phosphorus, and alkaline phosphatase (ALP) from baseline; the technical success rate; and complications. Univariate and multivariate logistic regression analyses were performed to identify independent prognostic factors affecting the prognosis of ablation.
resultsA total of 102 participants (mean age, 52 ± 12 years) with 174 hyperplastic parathyroid glands were evaluated. Overall, 87.3% of the participants achieved the target PTH level. Compared to baseline, significant reduction was achieved in PTH, calcium, phosphorus, and ALP levels (p < 0.05). The technical success rate was 100%. For major complications, one (1.0%) participant experienced persistent laryngeal nerve paralysis after ablation, and severe hypocalcemia occurred in 29 participants but did not result in serious comorbidities following calcium supplementation. The only independent predictor of treatment failure was baseline PTH ≥ 1606 pg/mL (odds ratio, 5.1; 95% CI: 1.1-23.1; p = 0.04).
conclusionsUS-guided thermal ablation is safe and effective for recurrent or persistent SHPT. Baseline PTH ≥ 1606 pg/mL is a key predictor of treatment failure. KEY POINTS: Question Recurrent/persistent SHPT lacks safe, minimally invasive therapies, while traditional repeat surgery poses high complication risks due to fibrosis and anatomical distortion. Findings The study demonstrated 87.3% in achieving target PTH levels. The incidence of severe hypocalcemia reached 28.4%. Clinical relevance This pioneering multicenter study with a large sample size demonstrates the long-term effectiveness and safety of US-guided percutaneous thermal ablation for treating recurrent and persistent SHPT. It offers a viable nonsurgical alternative for managing this condition.
Indexed as
Identifiers
40770142What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.